Firehawk®, Foxtrot® NC and Foxtrot® Pro PTCA Balloon Catheters Receive Approval in Turkmenistan

Ashgabat, Turkmenistan, 15 August 2021 - Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®) has recently received registration approval from the Turkmenistan Ministry of Health and Medical Industry for three of its proprietary products: the Firehawk® Rapamycin Target Eluting Coronary Stent System (Firehawk®), Foxtrot® NC PTCA Balloon Catheter (Foxtrot® NC), and Foxtrot® Pro PTCA Coronary Balloon Catheter (Foxtrot® Pro).

The approval of these three MicroPort® products in Turkmenistan shows industry recognition of MicroPort® for its outstanding product portfolio in the field of coronary intervention, further expanding the company’s global presence.

Firehawk® is a drug-eluting stent (DES) with patented grooved struts and precision targeting drug-releasing technology. It combines the advantages of the bare metal stent and drug-eluting stent, and allows for the precise injection of drugs into the micro-grooves by means of a fully automatic 3D-printed micro-groove filling, ensuring the effectiveness of the drug whilst significantly reducing the drug loading.

The Foxtrot® Pro Balloon Catheter is a rapid exchange balloon catheter designed to enlarge a patient’s lesion prior to stent implantation in percutaneous transluminal coronary angioplasty (PTCA) procedures. With excellent crossability and trackability, it offers additional solutions for more complex lesions. Its ultra-long hydrophilic coating improves its crossability and pushability, making it suitable for use in balloon-stent kissing techniques.

The Foxtrot® NC Balloon Catheter is suitable for both pre-dilation of culprit lesions prior to stent implantation and for precise post-dilation of stents after their implantation. Foxtrot® NC is a low-compliant balloon catheter and has a short deflation time. Super hydrophilic coating allows the catheter to move freely in vessels and reach the narrow lesion area smoothly, whilst two radiopaque markers aid in the positioning of the balloon under fluoroscopy during procedures. The catheter has excellent crossability, trackability and pushability.

About Shanghai Microport Medical (Group) Co., Ltd.

Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®), is a subsidiary of MicroPort Scientific Corporation (Group) Co., Ltd. (stock code: 00853.HK). As a leader in high-end innovative medical solutions, MicroPort® places emphasis on the human dimension while integrating the pursuit of perfection and innovation into the corporate DNA. In the future, MicroPort® will continue to pursue an innovative, people-centered culture to provide patients and physicians around the world with higher-quality, innovative high-end medical devices and integrated solutions.